CR11457A - Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos - Google Patents
Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismosInfo
- Publication number
- CR11457A CR11457A CR11457A CR11457A CR11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A CR 11457 A CR11457 A CR 11457A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- same
- bradykinin antagonists
- hialuronic acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000003152 bradykinin antagonist Substances 0.000 title 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Se describen las composiciones farmaceuticas que contienen, como ingredientes activos, una mezcla de un polimero de acýdo hialuronico con un antagonista del receptor de bradiquia B2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002225A ITMI20072225A1 (it) | 2007-11-23 | 2007-11-23 | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11457A true CR11457A (es) | 2010-11-05 |
Family
ID=40314753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11457A CR11457A (es) | 2007-11-23 | 2010-05-21 | Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9101627B2 (es) |
| EP (1) | EP2222275B1 (es) |
| JP (1) | JP5383695B2 (es) |
| KR (1) | KR101585868B1 (es) |
| CN (1) | CN101868225B (es) |
| AP (1) | AP2628A (es) |
| AR (1) | AR069407A1 (es) |
| AT (1) | ATE529096T1 (es) |
| AU (1) | AU2008328311B2 (es) |
| BR (1) | BRPI0820402A2 (es) |
| CA (1) | CA2706398C (es) |
| CL (1) | CL2008003475A1 (es) |
| CO (1) | CO6270301A2 (es) |
| CR (1) | CR11457A (es) |
| CY (1) | CY1112134T1 (es) |
| DK (1) | DK2222275T3 (es) |
| EA (1) | EA017626B1 (es) |
| EC (1) | ECSP10010153A (es) |
| ES (1) | ES2374861T3 (es) |
| GE (1) | GEP20125602B (es) |
| HN (1) | HN2010001037A (es) |
| HR (1) | HRP20110904T1 (es) |
| IL (1) | IL205860A (es) |
| IT (1) | ITMI20072225A1 (es) |
| MA (1) | MA31913B1 (es) |
| MX (1) | MX2010005484A (es) |
| MY (1) | MY148685A (es) |
| NI (1) | NI201000087A (es) |
| NZ (1) | NZ585514A (es) |
| PA (1) | PA8804801A1 (es) |
| PE (1) | PE20091422A1 (es) |
| PL (1) | PL2222275T3 (es) |
| PT (1) | PT2222275E (es) |
| RS (1) | RS52045B (es) |
| SI (1) | SI2222275T1 (es) |
| TN (1) | TN2010000215A1 (es) |
| TW (1) | TWI448292B (es) |
| UA (1) | UA97867C2 (es) |
| WO (1) | WO2009065507A2 (es) |
| ZA (1) | ZA201003586B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016028176A2 (pt) * | 2014-05-30 | 2017-08-22 | Mykolaivna Derkach Nataliia | solução estabilizada com base em duas substâncias ativas, método para preparar a solução estabilizada e composições farmacêuticas com base na solução estabilizada de substâncias ativas |
| CN107106594A (zh) * | 2014-12-26 | 2017-08-29 | 生化学工业株式会社 | 改善眼的自觉症状的制剂和方法 |
| US12371683B2 (en) | 2018-07-25 | 2025-07-29 | Alteogen Inc. | Hyaluronidase variants and pharmaceutical composition comprising the same |
| CN120053667A (zh) | 2019-03-25 | 2025-05-30 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| EP4194551A4 (en) | 2020-08-07 | 2024-08-28 | Alteogen, Inc. | PROCESS FOR PRODUCING RECOMBINANT HYALURONIDASE |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635489B2 (en) * | 2001-05-18 | 2009-12-22 | Leneau Holdings, Llc | Ingestion of hyaluronic acid for improved joint health |
| ITMI20021247A1 (it) * | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
-
2007
- 2007-11-23 IT IT002225A patent/ITMI20072225A1/it unknown
-
2008
- 2008-11-07 TW TW097142981A patent/TWI448292B/zh not_active IP Right Cessation
- 2008-11-10 AT AT08853047T patent/ATE529096T1/de active
- 2008-11-10 MX MX2010005484A patent/MX2010005484A/es active IP Right Grant
- 2008-11-10 WO PCT/EP2008/009451 patent/WO2009065507A2/en not_active Ceased
- 2008-11-10 BR BRPI0820402-0A patent/BRPI0820402A2/pt not_active IP Right Cessation
- 2008-11-10 GE GEAP200811807A patent/GEP20125602B/en unknown
- 2008-11-10 RS RS20110524A patent/RS52045B/sr unknown
- 2008-11-10 US US12/743,891 patent/US9101627B2/en not_active Expired - Fee Related
- 2008-11-10 EA EA201000678A patent/EA017626B1/ru not_active IP Right Cessation
- 2008-11-10 AP AP2010005265A patent/AP2628A/xx active
- 2008-11-10 JP JP2010534395A patent/JP5383695B2/ja not_active Expired - Fee Related
- 2008-11-10 DK DK08853047.2T patent/DK2222275T3/da active
- 2008-11-10 MY MYPI2010002358A patent/MY148685A/en unknown
- 2008-11-10 HR HR20110904T patent/HRP20110904T1/hr unknown
- 2008-11-10 NZ NZ585514A patent/NZ585514A/en not_active IP Right Cessation
- 2008-11-10 ES ES08853047T patent/ES2374861T3/es active Active
- 2008-11-10 CA CA2706398A patent/CA2706398C/en not_active Expired - Fee Related
- 2008-11-10 PL PL08853047T patent/PL2222275T3/pl unknown
- 2008-11-10 KR KR1020107011164A patent/KR101585868B1/ko not_active Expired - Fee Related
- 2008-11-10 SI SI200830475T patent/SI2222275T1/sl unknown
- 2008-11-10 EP EP08853047A patent/EP2222275B1/en active Active
- 2008-11-10 UA UAA201006127A patent/UA97867C2/ru unknown
- 2008-11-10 AU AU2008328311A patent/AU2008328311B2/en not_active Ceased
- 2008-11-10 PT PT08853047T patent/PT2222275E/pt unknown
- 2008-11-10 CN CN2008801169202A patent/CN101868225B/zh not_active Expired - Fee Related
- 2008-11-19 PE PE2008001955A patent/PE20091422A1/es not_active Application Discontinuation
- 2008-11-21 AR ARP080105077A patent/AR069407A1/es unknown
- 2008-11-21 PA PA20088804801A patent/PA8804801A1/es unknown
- 2008-11-21 CL CL2008003475A patent/CL2008003475A1/es unknown
-
2010
- 2010-05-05 EC EC2010010153A patent/ECSP10010153A/es unknown
- 2010-05-06 CO CO10054082A patent/CO6270301A2/es active IP Right Grant
- 2010-05-14 TN TN2010000215A patent/TN2010000215A1/fr unknown
- 2010-05-19 NI NI201000087A patent/NI201000087A/es unknown
- 2010-05-20 ZA ZA2010/03586A patent/ZA201003586B/en unknown
- 2010-05-20 IL IL205860A patent/IL205860A/en not_active IP Right Cessation
- 2010-05-20 HN HN2010001037A patent/HN2010001037A/es unknown
- 2010-05-21 CR CR11457A patent/CR11457A/es unknown
- 2010-06-15 MA MA32913A patent/MA31913B1/fr unknown
-
2011
- 2011-11-30 CY CY20111101177T patent/CY1112134T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY32036A (es) | Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
| CO6460772A2 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| ECSP12012042A (es) | Derivados de pirazol como inhibidores de jak | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| CL2012002355A1 (es) | Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih. | |
| PE20151437A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| GT201200321A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| CR20110599A (es) | Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos | |
| CO6420342A2 (es) | Derivados de pirazol usados como antagonistas del receptor ccr4 | |
| CR11457A (es) | Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos | |
| NI202000028A (es) | Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY32029A (es) | "derivados de pirazolo -[5.1-b] - oxazol, su prepraración, composiciones farmacéuticas que los contienen y aplicaciones" | |
| MX2019011545A (es) | Composiciones celulares y de andamio inyectables. | |
| CO6321246A2 (es) | Compuestos novedosos activos como antagonistas de receptor muscarinico | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| MX375183B (es) | Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas. | |
| CL2012001759A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica. | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| UY32410A (es) | Azetidinas como antagonistas del receptor de histamina3 | |
| UY33073A (es) | Nuevos derivados del tipo hexahidrociclopenta [ b]pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |